Inscopix Expands Strategic Partnership with GRINTECH to Become Exclusive Global Supplier of GRIN lenses

Inscopix, Inc., a neuroscience company helping decode the brain for tomorrow’s treatments, announced that it is expanding its strategic supplier partnership with leading gradient index (GRIN) lens manufacturer GRINTECH GmbH to be the sole exclusive seller of GRIN lenses for neuroscience research applications.

The company offers innovative miniature-microscope (miniscope) based imaging platforms and scientific consulting services for advancing neuroscience research, and with this partnership, hopes to bring to the broader scientific community the innovative GRIN-based lens technology that GRINTECH has pioneered.

In addiiton, the company has committed to continuing to support legacy GRINTECH customers with their micro-endoscope imaging needs across all non-human neuroscience research applications, and with this new agreement, Inscopix will serve any customer in the brain imaging research market. The partnership will also mean that Inscopix Field Scientific Consultants, Customer Support teams and the on-line support portal Inscopix iQ will now be available to all GRIN lens customers, irrespective of whether the user or lab is a customer of Inscopix’s miniscope-based platform.

“As a dedicated neuroscience partner, we are excited to be able to serve the broader research community with not just more GRIN lens products, but with our enhanced scientific support, customer service and volume-based pricing discounts,” said Kunal Ghosh, Ph.D., CEO of Inscopix. ”The expansion of our partnership with GRINTECH also represents a natural evolution of the long-standing relationship our two companies have had.”

Inscopix’s technology is already in use by basic and translational researchers in more than 600 labs in both academia and pharma, which have produced almost 200 publications describing many breakthrough discoveries about brain function and disorders. By uncovering the connections between neurons, the company and its collaborators are able to gain insights into directly actionable targets for therapeutic intervention to treat brain-related diseases.

“This partnership allows our customers to get a higher quality product with support and resources built in, and we’re looking forward to this improved buyer experience,” said Bernhard Messerschmidt, Ph.D., CEO of GRINTECH GmbH.

Medical Device News Magazine
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Data from clinical studies of STK-001 demonstrated clinical benefit for patients ages 2 to 18 years old, including reductions in seizures and improvements in cognition and behavior that support the potential for disease modificatio. Analysis of 72 patients treated in STK-001 clinical trials suggests that higher STK-001 drug exposure in brain leads to greater seizure reductions. Two-year data from the longest prospective natural history study of Dravet syndrome showed that, on average, patients experienced no meaningful improvement in convulsive seizure frequency and exhibited widening gaps in cognition and behavior despite treatment with the best available anti-seizure medicines.
"Exact Sciences is looking forward to presenting new evidence at SABCS that adds important perspectives to treating breast cancer patients and showing that some patients may be able to de-escalate treatments and still have positive outcomes," said Dr. Rick Baehner, Chief Medical Officer, Precision Oncology, Exact Sciences. "Every year, we build upon the precedent set by the Oncotype DX Breast Recurrence Score® test and its prognostic and predictive abilities to determine the chemotherapy benefit for specific breast cancer patients. We are pleased to see authorities expanding access to this test as we continue to develop key evidence in collaboration with some of the world's most prestigious, breast cancer-focused organizations."
Clozapine has been established as the most effective antipsychotic medication for treatment-resistant schizophrenia. However, it is significantly underutilized mainly due to the risk of developing agranulocytosis and the need to frequently monitor the absolute neutrophil count (ANC).
Dagi-Ben Noon, CEO of Inspira Technologies, reflects on the partnership's significance: "By Integrating our technology to oxygenate blood directly with Ennocure's infection prevention solutions, we are focusing on potentially improving patient outcomes in ICUs and paving the way for safer, more effective life-support treatments. This collaboration is expected to accelerate the development and broaden the implementation of our advanced technology."
The findings suggest that the novel, non-invasive genomic test can help physicians guide next steps for these patients, enabling them to potentially avoid unnecessary invasive procedures or accelerate time to appropriate treatment.

By using this website you agree to accept Medical Device News Magazine Privacy Policy